Ketoacidosis associated with SGLT2 inhibitor treatment: Analysis of FAERS data

Our results support the FDA's warning that SGLT2 inhibitors lead to ketoacidosis, as evidenced by an increased reporting rate for acidosis above that in a comparator population treated with DPP4 inhibitors.